{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:28:35Z","timestamp":1790616515545,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2831,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hvidovre Hospital Foundation for Liver Disease"},{"name":"Ferring Pharmaceuticals Inc."},{"DOI":"10.13039\/501100001734","name":"University of Copenhagen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,12]]},"abstract":"\n \n \n Patients with advanced cirrhosis and ascites are characterized by circulatory dysfunction with splanchnic vasodilatation and renal vasoconstriction, which often lead to ascites. The vasoconstrictor terlipressin improves renal function in hepatorenal syndrome (HRS). The aim of this study was to evaluate if terlipressin also improves renal function in patients with ascites without HRS. Twenty-three patients with cirrhosis participated; 15 with nonrefractory ascites were randomized to either terlipressin (N group, n = 11) or a placebo (P group, n = 4), and 8 had refractory ascites and received terlipressin (R group). The glomerular filtration rate (GFR), sodium clearance (<\/jats:bold>\n \n C\n <\/jats:bold>\n \n Na), lithium clearance (<\/jats:bold>\n \n C\n <\/jats:bold>\n \n Li), osmolal clearance (<\/jats:bold>\n \n C\n <\/jats:bold>\n \n Osm), and urine sodium concentration (<\/jats:bold>\n \n U\n <\/jats:bold>\n \n Na) were assessed before and after the injection of 2 mg of terlipressin or the placebo. GFR increased in the N group (69 \u00b1 19 versus 92 \u00b1 25 mL\/min,<\/jats:bold>\n \n P\n <\/jats:bold>\n < 0.005) and in the R group (31 \u00b1 19 versus 41 \u00b1 31 mL\/min,<\/jats:bold>\n \n P\n <\/jats:bold>\n < 0.05) after terlipressin. In the N group, terlipressin induced an increase in<\/jats:bold>\n \n C\n <\/jats:bold>\n \n Na (0.89 \u00b1 0.21 versus 1.52 \u00b1 1.45 mL\/min,<\/jats:bold>\n \n P\n <\/jats:bold>\n < 0.05),<\/jats:bold>\n \n C\n <\/jats:bold>\n \n Li (17.3 \u00b1 8.9 versus 21.5 \u00b1 11.6 mL\/min,<\/jats:bold>\n \n P\n <\/jats:bold>\n < 0.05), and<\/jats:bold>\n \n C\n <\/jats:bold>\n \n Osm (2.10 \u00b1 0.81 versus 3.06 \u00b1 2.0 mL\/min,<\/jats:bold>\n \n P\n <\/jats:bold>\n < 0.05). In the R group, terlipressin induced an increase in<\/jats:bold>\n \n C\n <\/jats:bold>\n \n Na (0.11 \u00b1 0.18 versus 0.35 \u00b1 0.40 mL\/min,<\/jats:bold>\n \n P\n <\/jats:bold>\n < 0.05) and<\/jats:bold>\n \n C\n <\/jats:bold>\n \n Li (5.5 \u00b1 4.2 versus 9.5 \u00b1 8.55 mL\/min,<\/jats:bold>\n \n P\n <\/jats:bold>\n < 0.05).<\/jats:bold>\n \n U\n <\/jats:bold>\n \n Na increased in both groups after terlipressin (<\/jats:bold>\n \n P\n <\/jats:bold>\n < 0.005). Plasma norepinephrine (<\/jats:bold>\n \n P\n <\/jats:bold>\n < 0.05) and renin (<\/jats:bold>\n \n P\n <\/jats:bold>\n < 0.05) decreased after terlipressin. All parameters remained unchanged after the placebo.<\/jats:bold>\n \n Conclusion:\n <\/jats:bold>\n The vasopressin 1 receptor agonist terlipressin improves renal function and induces natriuresis in patients with cirrhosis and ascites without HRS. Vasoconstrictors may represent a novel future treatment modality for these patients. (Hepatology 2007.)<\/jats:bold>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/hep.21901","type":"journal-article","created":{"date-parts":[[2007,11,20]],"date-time":"2007-11-20T23:17:55Z","timestamp":1195600675000},"page":"1863-1871","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":123,"title":["Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome"],"prefix":"10.1097","volume":"46","author":[{"given":"Aleksander","family":"Krag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u03c6ren","family":"M\u03c6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens H.","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels-Henrik","family":"Holstein-Rathlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fin Stolze","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"Bendtsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20241201","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01320309","article-title":"Survival and prognostic indicators in compensated and decompensated cirrhosis.","volume":"31","author":"DAmico","year":"1986","journal-title":"Dig Dis Sci"},{"key":"R2-25-20241201","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.1840070124","article-title":"Compensated cirrhosis: natural history and prognostic factors.","volume":"7","author":"Gines","year":"1987","journal-title":"Hepatology"},{"key":"R3-25-20241201","first-page":"164","article-title":", for the International Ascites Club. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"R4-25-20241201","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology"},{"key":"R5-25-20241201","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMra035021","article-title":"Management of cirrhosis and ascites.","volume":"350","author":"Gines","year":"2004","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R6-25-20241201","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0168-8278(03)00007-2","article-title":"Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management.","volume":"38","author":"Arroyo","year":"2003","journal-title":"J Hepatol"},{"key":"R7-25-20241201","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00042737-200202000-00009","article-title":"Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.","volume":"14","author":"Halimi","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R8-25-20241201","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","article-title":"Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.","volume":"122","author":"Moreau","year":"2002","journal-title":"Gastroenterology"},{"key":"R9-25-20241201","first-page":"15","article-title":"Longterm terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.","volume":"64","author":"Mulkay","year":"2001","journal-title":"Acta Gastroenterol Belg"},{"key":"R10-25-20241201","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.","volume":"36","author":"Ortega","year":"2002","journal-title":"Hepatology"},{"key":"R11-25-20241201","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebocontrolled clinical trial.","volume":"18","author":"Solanki","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R12-25-20241201","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","article-title":"Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.","volume":"33","author":"Uriz","year":"2000","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"R13-25-20241201","first-page":"LB6","article-title":"A prospective, randomized, double blind, placebocontrolled trial of terlipressin for type 1 hepatorenal syndrome.","volume":"44","author":"Sanyal","year":"2006","journal-title":"Hepatology"},{"key":"R14-25-20241201","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1034\/j.1600-0676.2000.020001051.x","article-title":"Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients.","volume":"20","author":"Moller","year":"2000","journal-title":"Liver"},{"key":"R15-25-20241201","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/jhep.2003.50315","article-title":"The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club.","volume":"38","author":"Moore","year":"2003","journal-title":"Hepatology"},{"key":"R16-25-20241201","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/hep.20066","article-title":"Management of adult patients with ascites due to cirrhosis.","volume":"39","author":"Runyon","year":"2004","journal-title":"Hepatology"},{"key":"R17-25-20241201","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000183252","article-title":"Lithium clearance: a new method for determining proximal and distal tubular reabsorption of sodium and water.","volume":"37","author":"Thomsen","year":"1984","journal-title":"Nephron"},{"key":"R18-25-20241201","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0168-8278(96)80118-8","article-title":"Effect of oxygen inhalation on systemic, central, and splanchnic haemodynamics in cirrhosis.","volume":"25","author":"Moller","year":"1996","journal-title":"J Hepatol"},{"key":"R19-25-20241201","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/hep.1840400410","article-title":"Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis.","volume":"40","author":"Moller","year":"2004","journal-title":"Hepatology"},{"key":"R20-25-20241201","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/0168-8278(91)90920-7","article-title":"Increased circulating calcitonin generelated peptide (CGRP) in cirrhosis.","volume":"12","author":"Bendtsen","year":"1991","journal-title":"J Hepatol"},{"key":"R21-25-20241201","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/01.HYP.0000017552.91014.2A","article-title":"Plasma ProANP(130) reflects salt sensitivity in subjects with heredity for hypertension.","volume":"39","author":"Melander","year":"2002","journal-title":"Hypertension"},{"key":"R22-25-20241201","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/jhep.2001.26754","article-title":"Effects of a longacting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, doubleblind, controlled trial.","volume":"34","author":"Ottesen","year":"2001","journal-title":"Hepatology"},{"key":"R23-25-20241201","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0168-8278(97)80456-4","article-title":"Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites.","volume":"26","author":"Gadano","year":"1997","journal-title":"J Hepatol"},{"key":"R24-25-20241201","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jhep.2006.09.012","article-title":"Effects of a 7day treatment with midodrine in nonazotemic cirrhotic patients with and without ascites.","volume":"46","author":"Kalambokis","year":"2007","journal-title":"J Hepatol"},{"key":"R25-25-20241201","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.510280407","article-title":"Acute effects of the oral administration of midodrine, an alphaadrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.","volume":"28","author":"Angeli","year":"1998","journal-title":"Hepatology"},{"key":"R26-25-20241201","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0168-8278(89)90024-X","article-title":"Renal function and effective betablockade in cirrhosis with ascites. Relationship with baseline sympathoadrenergic tone.","volume":"8","author":"Bernardi","year":"1989","journal-title":"J Hepatol"},{"key":"R27-25-20241201","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/gut.42.2.283","article-title":"Acute effect of propranolol and isosorbide5mononitrate administration on renal blood flow in cirrhotic patients.","volume":"42","author":"Stanley","year":"1998","journal-title":"Gut"},{"key":"R28-25-20241201","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1006\/bbrc.1994.2150","article-title":"Cloning, functional expression and tissue distribution of human cDNA for the vasculartype vasopressin receptor.","volume":"203","author":"Hirasawa","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"R29-25-20241201","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/00365520310008728","article-title":"Effect of terlipressin on blood volume distribution in patients with cirrhosis.","volume":"39","author":"KiszkaKanowitz","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"R30-25-20241201","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000190264","article-title":"The validity of lithium clearance as an index of sodium and water delivery from the proximal tubules.","volume":"77","author":"Thomsen","year":"1997","journal-title":"Nephron"},{"key":"R31-25-20241201","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/hep.1840150416","article-title":"Effects of amiloride on renal lithium handling in nonazotemic ascitic cirrhotic patients with avid sodium retention.","volume":"15","author":"Angeli","year":"1992","journal-title":"Hepatology"},{"key":"R32-25-20241201","doi-asserted-by":"crossref","first-page":"413","DOI":"10.7326\/0003-4819-96-4-413","article-title":"Role of vasopressin in abnormal water excretion in cirrhotic patients.","volume":"96","author":"Bichet","year":"1982","journal-title":"Ann Intern Med"},{"key":"R33-25-20241201","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1126\/science.2990050","article-title":"Vasopressinstimulated release of atriopeptin: endocrine antagonists in fluid homeostasis.","volume":"229","author":"Manning","year":"1985","journal-title":"Science"},{"key":"R34-25-20241201","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJM198212163072504","article-title":"Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis.","volume":"307","author":"Bichet","year":"1982","journal-title":"N Engl J Med"},{"key":"R35-25-20241201","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1152\/physrev.1990.70.4.1067","article-title":"Morphology, physiology, and molecular biology of renin secretion.","volume":"70","author":"Hackenthal","year":"1990","journal-title":"Physiol Rev"},{"key":"R36-25-20241201","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1172\/JCI104624","article-title":"The metabolism of aldosterone in normal subjects and in patients with hepatic cirrhosis.","volume":"41","author":"Coppage","year":"1962","journal-title":"J Clin Invest"},{"key":"R37-25-20241201","first-page":"241","article-title":"Secretion and turnover of aldosterone in various pathological states.","volume":"36","author":"Vecsei","year":"1969","journal-title":"Clin Sci"},{"key":"R38-25-20241201","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000094539","article-title":"Vasopressin antagonists: role in the management of hyponatremia.","volume":"26","author":"Yeates","year":"2006","journal-title":"Am J Nephrol"},{"key":"R39-25-20241201","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2receptor antagonist, for hyponatremia.","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21901","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200712000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:12:44Z","timestamp":1733058764000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200712000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21901","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}